Navigation Links
Study of Long-Term Efficacy and Safety of New PyratineXR™ Moisturizing Lotion Featured in Journal of Drugs in Dermatology

NAPA, Calif., July 15 /PRNewswire/ -- The June 2010 issue of Journal of Drugs in Dermatology (JDD), a full-color, peer-reviewed publication serving the dermatology community, features a study on the long-term efficacy and tolerability of the active ingredient in PyratineXR™.  The results of the 48-week clinical study demonstrate that PyratineXR™ Moisturizing Lotion, the flagship product in the new advanced skincare line that is Pyratine LLC's next generation of Cytokinin-based skincare technology is effective and well-tolerated for individuals suffering from inflammatory skin conditions such as acne, rosacea, sunburn and razor burn.

(Photo: )

(Photo: )

Study Abstract: The rosacea-specific study entitled "Long-term Efficacy and Safety of Topical PRK-124 (0.125%) Lotion (PyratineXR™) in the Treatment of Mild-to-Moderate Rosacea," was performed at the University of California, Irvine.  Many patients with rosacea cannot tolerate extended treatment periods with topical agents because their skin sensitivity is often increased.   The objective of the study was to determine the long-term efficacy and tolerability of PyratineXR™ for improving the signs and symptoms of mild-to-moderate rosacea.   In the 48-week, open-label study, a moisturizing lotion containing furfuryl tetrahydropyranyladenine as PRK-124 (0.125%, PyratineXR™) was applied twice daily by 18 subjects with mild-to-moderate rosacea.  Clinical improvements were assessed by the treating physicians. Skin barrier function was measured by transepidermal water loss after treatment. Tolerability and cosmetic outcome were evaluated by subjects.  Subjects experienced a mean 44 percent reduction in erythema severity and a mean 89 percent reduction in inflammatory lesion count at week 48. Reductions were significant (P less than or equal to 0.05) in both erythema and lesions at weeks 24, 36 and 48. Statistically significant (P less than or equal to 0.05) improvements in telangiectasia (spider veins), transepidermal water loss and dryness were noted. Overall clinical improvement was observed in 81 percent of subjects and the investigator's global assessment steadily improved throughout the study. Treatments were well tolerated and esthetically pleasing. Treatment-induced skin irritation was not observed. The published study concludes that PyratineXR™ is efficacious, does not irritate skin, and is well tolerated for continuous long term treatment.

"Having a topical solution that is non-irritating which can be used continuously long-term without the need for interruption is truly a breakthrough for the millions of people suffering from inflammatory skin conditions such as rosacea and acne," said Frank J. Massino, Founder and Chief Executive Officer of Pyratine LLC.  "While the causes of many of these conditions, such as rosacea, are unknown and there is no cure, we are pleased that our scientific advancement is recognized by the medical community through such a prestigious publication as the JDD, but more importantly, that PyratineXR™ offers sufferers hope and a way to control the signs and symptoms of these potentially life-disruptive disorders."

Created by the original developers of kinetin (Brand name Kinerase, Marketed by Valeant Pharmaceuticals), PyratineXR™ is a new advanced generation of cytokinins for therapeutic skin care. PyratineXR™ is clinically proven to relieve redness (erythema), soothe irritation, increase moisture and repair damaged skin quickly and effectively.  Clinical studies have demonstrated that PyratineXR™ significantly reduces the appearance of lesions (papules and pustules), spider veins and dark spots, while improving skin texture in just days.

The PyratineXR™ line, which includes a lotion, creme and a new specially formulated cleanser for sensitive skin is now available nationwide through select dermatologists, physicians, as well as online at  

The Journal of Drugs in Dermatology (JDD), a full-color, peer-reviewed publication indexed with MEDLINE®/PubMed®, was founded by the renowned Dr. Perry Robins, MD. Now in its eighth year, it offers one of the fastest routes to disseminate dermatologic information, and is considered the fastest growing publication in dermatology.  JDD presents original articles, award-winning case reports, and timely features pertaining to new methods, techniques, and drug therapy in dermatology, which provides readers with peer-reviewed content of the utmost quality.  JDD's high standards of content are maintained through a balanced, peer-review process. Articles are reviewed by an International Editorial Board of over 150 renowned experts. JDD reaches approximately 14,500 dermatology healthcare professionals and has been recognized as the official publication of the International Society of Dermatologic Surgery (ISDS) and the Orlando Dermatology Aesthetic and Clinical (ODAC) Conference.  The extremely current and practical editorial content of JDD results in high readership and maximum exposure among the dermatology community.

About Pyratine LLC:

Pyratine LLC, instrumental in helping develop the leading selling and proprietary anti-aging compound (Ingredient: Kinetin; Brand: Kinerase) in the Physician Market in North America, now offers its new advanced cytokinin (a class of plant growth factors), Tetrahydropyranyl Adenine, potentially both as a branded product (Pyratine-6 and PyratineXR) or private label for distribution worldwide.  Pyratine-6 and PyratineXR successfully launched in the Dispensing Physician Market in North America.

Pyratine LLC prides itself in its science, safety testing all compounds in discovery along the lines of FDA testing requirements for a New Drug Application. Pyratine LLC offers a key differential advantage over most every other cosmetic and cosmeceutical product as each and every ingredient presented by Pyratine LLC has been the subject of rigorous multi-site human safety and efficacy testing.  For more information, visit the company's websites -- and

This news release contains statements that may be considered 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company's Annual Report on Form 10-K for the year 2008. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward-looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise.

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, Inc. ... clinical-stage biopharmaceutical company developing new treatments for cancer ... closing of its previously announced underwritten public offering ... a public offering price of $2.00 per share, ... offering expenses payable by Sorrento.  The net proceeds ...
(Date:4/18/2017)... -- Cardinal Health (NYSE: CAH ) today is ... share (EPS) guidance and providing a preliminary view on ... this morning,s announcement of the planned acquisition of Medtronic,s ... Cardinal Health now believes that fiscal 2017 ... bottom of its previous guidance range of $5.35 to ...
(Date:4/18/2017)... BLOOMINGTON, Minn. , April 18, ... IMMY ) ("Imprimis"), an ophthalmology-focused pharmaceutical company, and ... today announced the signing of a three-year exclusive ... will deploy a dedicated sales team to introduce ... U.S., primarily focused in 13 states in the ...
Breaking Medicine Technology:
(Date:4/21/2017)... ... 2017 , ... Crossover Symmetry , an evidence based ... lifestyle company that provides Human Performance Training and education to tactical athletes. Together ... military officers and others in service through the development and conditioning of overall ...
(Date:4/21/2017)... ... April 21, 2017 , ... Northern California Medical ... Care Spring Symposium on April 1, 2017 in Santa Rosa. This well-attended annual ... healthcare providers an opportunity to learn about cutting edge treatments, to collaborate, share ...
(Date:4/21/2017)... ... April 21, 2017 , ... BrightStar Care Salt Lake City, a ... Care of Utah (APCUT) and has appointed Rex Wheeler as its new Director of ... for our agency and our ability to provide quality care to the community,” said ...
(Date:4/21/2017)... ... , ... During April 21-23, Super-Sod will join the vendor market of the ... everyone — from the avid gardener to the landscape admirer — during the three-day ... in a grand venue, and we are certainly looking forward to participating in this ...
(Date:4/21/2017)... ... April 21, 2017 , ... National pest management association survey conducted ... of bed bug infestations over the 5-year period. In 2015 10% or US$750 million ... of bed bug infested properties. , The health and economic consequences of bed ...
Breaking Medicine News(10 mins):